

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the Query Builder analysis.

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview

Query Builder Report: This report details the results of an analysis generated by the Sentinel Query Builder application. Query Builder enables FDA to visualize, draft, and create standardized medical product utilization queries examining dispensing patterns and cohort characteristics using a set of pre-defined parameters. This is a Type 5 (Medical Product Utilization) analysis as described in the Query Request Package (QRP) documentation.

Data Source: We executed this request on IBM® MarketScan® Commercial Claims and Encounters Database and Medicare Supplemental Database, which included 142 million members, on September 23, 2020. The study period included data from January 1, 2013 to March 31, 2019. Please see Appendix A for data availability dates.

Request Description: In this request, we described utilization patterns of mixed amphetamine salts immediate-release tablets by manufacturer. Please see Appendix B for the specifications of parameters used in this request.

We defined the mixed amphetamine salts immediate-release tablet exposures using National Drug Codes (NDCs). Please see Appendix C for a list of NDCs used to define the products evaluated in this request.

We required evidence of a narcolepsy/attention deficit hyperactivity disorder (ADHD) diagnosis in the 183 days prior to the index dispensing. We defined this inclusion requirement using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. Please see Appendix D for the specific diagnosis codes used.

We required patients to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort. Gaps in treatment episodes were allowed and varied by cohort: up to 14 days, up to 7 days, or no gap in coverage. Treatment episode extensions were also allowed; for all cohorts, the episode extension length was equal to the gap length.

This is Report 1 of 2. Report 2 details utilization of mixed amphetamine immediate-release tablets for an additional ten cohorts, by product manufacturer.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 9.1.0.

Limitations: Algorithms used to define exposures and inclusion and exclusion criteria are imperfect; thus it is possible that there may be misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel Query Builder, please refer to the documentation (<https://dev.sentinelssystem.org/projects/QB/repos/querybuilder/browse>).

Table of contents	
Table 1a	Baseline table (Barr Mixed Amphetamine Salt, 0 Day Gap)
Table 1b	Baseline table (Barr Mixed Amphetamine Salt, 7 Day Gap)
Table 1c	Baseline table (Barr Mixed Amphetamine Salt, 14 Day Gap)
Table 1d	Baseline table (NorthstarRx Mixed Amphetamine Salt, 0 Day Gap)
Table 1e	Baseline table (NorthstarRx Mixed Amphetamine Salt, 7 Day Gap)
Table 1f	Baseline table (NorthstarRx Mixed Amphetamine Salt, 14 Day Gap)
Table 1g	Baseline table (Sandoz Mixed Amphetamine Salt, 0 Day Gap)
Table 1h	Baseline table (Sandoz Mixed Amphetamine Salt, 7 Day Gap)
Table 1i	Baseline table (Sandoz Mixed Amphetamine Salt, 14 Day Gap)
Table 1j	Baseline table (SpecGx Mixed Amphetamine Salt, 0 Day Gap)
Table 2a	Descriptive statistics of cumulative exposure duration, all episodes, in days
Table 2b	Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex
Table 2c	Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)
Table 3a	Descriptive statistics of first exposure episode duration, in days
Table 3b	Descriptive statistics of first exposure episode duration, in days, by sex
Table 3c	Descriptive statistics of first exposure episode duration, in days, by age group (years)
Table 4a	Descriptive statistics of all episode durations, in days
Table 4b	Descriptive statistics of all episode durations, in days, by sex
Table 4c	Descriptive statistics of all episode durations, in days, by age group (years)
Table 5a	Descriptive statistics of days supplied per dispensing
Table 5b	Descriptive statistics of days supplied per dispensing, by sex
Table 5c	Descriptive statistics of days supplied per dispensing, by age group (years)
Table 6a	Descriptive statistics of the length of all gaps between treatment episodes, in days
Table 6b	Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex
Table 6c	Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)
Table 7	Counts of reason for censoring, all episodes and first episode
Table 8	Cohort Attrition Table
Appendix A	Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2019) as of Query Distribution Date
Appendix B	Specifications Used to Define Parameters in this Query
Appendix C	List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request
Appendix D	List of International Classifications of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classifications of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Table 1a: Baseline table (Barr Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	840	
Demographics		
Mean Age (years)	25.6	14.8
Age (years): 00-01	0	0.0%
Age (years): 02-04	4	0.5%
Age (years): 05-09	105	12.5%
Age (years): 10-14	134	16.0%
Age (years): 15-18	90	10.7%
Age (years): 19-21	83	9.9%
Age (years): 22-44	312	37.1%
Age (years): 45-64	106	12.6%
Age (years): 65-74	6	0.7%
Age (years): 75+	0	0.0%
Sex (Female)	400	47.6%
Sex (Male)	440	52.4%
Year (2013)	443	52.7%
Year (2014)	356	42.4%
Year (2015)	30	3.6%
Year (2016)	4	0.5%
Year (2017)	7	0.8%
Year (2018)	0	0.0%
Year (2019)	0	0.0%
Recorded history of:		
Prior combined comorbidity score ³	0.2	0.6
Acquired Hypothyroidism	36	4.3%
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	0	0.0%
Anemia	17	2.0%
Asthma	59	7.0%
Atrial Fibrillation	0	0.0%
Benign Prostatic Hyperplasia	2	0.2%
Breast Cancer	4	0.5%
Cataracts	6	0.7%
Chronic Kidney Disease	4	0.5%
Chronic Obstructive Pulmonary Disease	6	0.7%
Colorectal Cancer	1	0.1%
Depression	137	16.3%
Diabetes	13	1.5%
Endometrial Cancer	0	0.0%
Glaucoma	2	0.2%
Heart Failure	0	0.0%
Hip / Pelvic Fracture	1	0.1%
Hyperlipidemia	35	4.2%
Hypertension	39	4.6%
Ischemic Heart Disease	2	0.2%
Lung Cancer	0	0.0%
Osteoporosis	5	0.6%
Prostate Cancer	1	0.1%
Rheumatoid Arthritis / Osteoarthritis	32	3.8%
Stroke / Transient Ischemic Attack	0	0.0%

Table 1a: Baseline table (Barr Mixed Amphetamine Salt, 0 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	8.4	9.0
Mean number of emergency room encounters (ED)	0.2	0.7
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	1.0	4.8
Mean number of filled prescriptions	13.6	11.0
Mean number of generics	4.5	3.7
Mean number of unique drug classes	4.3	3.3

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1b: Baseline table (Barr Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	828	
Demographics		
Mean Age (years)	25.6	14.8
Age (years): 00-01	0	0.0%
Age (years): 02-04	4	0.5%
Age (years): 05-09	104	12.6%
Age (years): 10-14	131	15.8%
Age (years): 15-18	88	10.6%
Age (years): 19-21	83	10.0%
Age (years): 22-44	308	37.2%
Age (years): 45-64	104	12.6%
Age (years): 65-74	6	0.7%
Age (years): 75+	0	0.0%
Sex (Female)	394	47.6%
Sex (Male)	434	52.4%
Year (2013)	431	52.1%
Year (2014)	356	43.0%
Year (2015)	30	3.6%
Year (2016)	4	0.5%
Year (2017)	7	0.8%
Year (2018)	0	0.0%
Year (2019)	0	0.0%
Recorded history of:		
Prior combined comorbidity score ³	0.2	0.6
Acquired Hypothyroidism	36	4.3%
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	0	0.0%
Anemia	17	2.1%
Asthma	57	6.9%
Atrial Fibrillation	0	0.0%
Benign Prostatic Hyperplasia	2	0.2%
Breast Cancer	4	0.5%
Cataracts	6	0.7%
Chronic Kidney Disease	5	0.6%
Chronic Obstructive Pulmonary Disease	7	0.8%
Colorectal Cancer	1	0.1%
Depression	135	16.3%
Diabetes	13	1.6%
Endometrial Cancer	0	0.0%
Glaucoma	2	0.2%
Heart Failure	0	0.0%
Hip / Pelvic Fracture	1	0.1%
Hyperlipidemia	35	4.2%
Hypertension	38	4.6%
Ischemic Heart Disease	2	0.2%
Lung Cancer	0	0.0%
Osteoporosis	5	0.6%
Prostate Cancer	1	0.1%
Rheumatoid Arthritis / Osteoarthritis	30	3.6%
Stroke / Transient Ischemic Attack	0	0.0%

Table 1b: Baseline table (Barr Mixed Amphetamine Salt, 7 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	8.4	9.0
Mean number of emergency room encounters (ED)	0.2	0.7
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	1.0	4.8
Mean number of filled prescriptions	13.5	10.9
Mean number of generics	4.5	3.7
Mean number of unique drug classes	4.3	3.3

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1c: Baseline table (Barr Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	822	
Demographics		
Mean Age (years)	25.6	14.8
Age (years): 00-01	0	0.0%
Age (years): 02-04	4	0.5%
Age (years): 05-09	103	12.5%
Age (years): 10-14	130	15.8%
Age (years): 15-18	88	10.7%
Age (years): 19-21	83	10.1%
Age (years): 22-44	305	37.1%
Age (years): 45-64	103	12.5%
Age (years): 65-74	6	0.7%
Age (years): 75+	0	0.0%
Sex (Female)	389	47.3%
Sex (Male)	433	52.7%
Year (2013)	427	51.9%
Year (2014)	354	43.1%
Year (2015)	30	3.6%
Year (2016)	4	0.5%
Year (2017)	7	0.9%
Year (2018)	0	0.0%
Year (2019)	0	0.0%
Recorded history of:		
Prior combined comorbidity score ³	0.2	0.6
Acquired Hypothyroidism	36	4.4%
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	0	0.0%
Anemia	17	2.1%
Asthma	57	6.9%
Atrial Fibrillation	0	0.0%
Benign Prostatic Hyperplasia	2	0.2%
Breast Cancer	4	0.5%
Cataracts	6	0.7%
Chronic Kidney Disease	5	0.6%
Chronic Obstructive Pulmonary Disease	6	0.7%
Colorectal Cancer	1	0.1%
Depression	135	16.4%
Diabetes	13	1.6%
Endometrial Cancer	0	0.0%
Glaucoma	2	0.2%
Heart Failure	0	0.0%
Hip / Pelvic Fracture	1	0.1%
Hyperlipidemia	34	4.1%
Hypertension	37	4.5%
Ischemic Heart Disease	2	0.2%
Lung Cancer	0	0.0%
Osteoporosis	5	0.6%
Prostate Cancer	1	0.1%
Rheumatoid Arthritis / Osteoarthritis	29	3.5%
Stroke / Transient Ischemic Attack	0	0.0%

Table 1c: Baseline table (Barr Mixed Amphetamine Salt, 14 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	8.4	9.0
Mean number of emergency room encounters (ED)	0.2	0.7
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	1.0	4.8
Mean number of filled prescriptions	13.5	10.9
Mean number of generics	4.5	3.7
Mean number of unique drug classes	4.3	3.3

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1d: Baseline table (NorthstarRx Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	8,292	
Demographics		
Mean Age (years)	34.7	13.7
Age (years): 00-01	0	0.0%
Age (years): 02-04	5	0.1%
Age (years): 05-09	202	2.4%
Age (years): 10-14	409	4.9%
Age (years): 15-18	412	5.0%
Age (years): 19-21	497	6.0%
Age (years): 22-44	4,772	57.5%
Age (years): 45-64	1,960	23.6%
Age (years): 65-74	31	0.4%
Age (years): 75+	4	0.0%
Sex (Female)	4,219	50.9%
Sex (Male)	4,073	49.1%
Year (2013)	0	0.0%
Year (2014)	0	0.0%
Year (2015)	0	0.0%
Year (2016)	0	0.0%
Year (2017)	0	0.0%
Year (2018)	4,521	54.5%
Year (2019)	3,771	45.5%
Recorded history of:		
Prior combined comorbidity score ³	0.4	0.9
Acquired Hypothyroidism	475	5.7%
Acute Myocardial Infarction	4	0.0%
Alzheimer's Disease	1	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	11	0.1%
Anemia	247	3.0%
Asthma	391	4.7%
Atrial Fibrillation	16	0.2%
Benign Prostatic Hyperplasia	53	0.6%
Breast Cancer	30	0.4%
Cataracts	72	0.9%
Chronic Kidney Disease	186	2.2%
Chronic Obstructive Pulmonary Disease	148	1.8%
Colorectal Cancer	4	0.0%
Depression	2,123	25.6%
Diabetes	282	3.4%
Endometrial Cancer	1	0.0%
Glaucoma	52	0.6%
Heart Failure	20	0.2%
Hip / Pelvic Fracture	3	0.0%
Hyperlipidemia	840	10.1%
Hypertension	1,157	14.0%
Ischemic Heart Disease	68	0.8%
Lung Cancer	0	0.0%
Osteoporosis	19	0.2%
Prostate Cancer	6	0.1%
Rheumatoid Arthritis / Osteoarthritis	553	6.7%
Stroke / Transient Ischemic Attack	24	0.3%

Table 1d: Baseline table (NorthstarRx Mixed Amphetamine Salt, 0 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.5
Mean number of filled prescriptions	13.5	11.3
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1e: Baseline table (NorthstarRx Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	8,190	
Demographics		
Mean Age (years)	34.7	13.7
Age (years): 00-01	0	0.0%
Age (years): 02-04	5	0.1%
Age (years): 05-09	202	2.5%
Age (years): 10-14	406	5.0%
Age (years): 15-18	409	5.0%
Age (years): 19-21	493	6.0%
Age (years): 22-44	4,717	57.6%
Age (years): 45-64	1,924	23.5%
Age (years): 65-74	30	0.4%
Age (years): 75+	4	0.0%
Sex (Female)	4,161	50.8%
Sex (Male)	4,029	49.2%
Year (2013)	0	0.0%
Year (2014)	0	0.0%
Year (2015)	0	0.0%
Year (2016)	0	0.0%
Year (2017)	0	0.0%
Year (2018)	4,477	54.7%
Year (2019)	3,713	45.3%
Recorded history of:		
Prior combined comorbidity score ³	0.4	0.9
Acquired Hypothyroidism	472	5.8%
Acute Myocardial Infarction	4	0.0%
Alzheimer's Disease	1	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	11	0.1%
Anemia	243	3.0%
Asthma	388	4.7%
Atrial Fibrillation	16	0.2%
Benign Prostatic Hyperplasia	53	0.6%
Breast Cancer	27	0.3%
Cataracts	68	0.8%
Chronic Kidney Disease	184	2.2%
Chronic Obstructive Pulmonary Disease	146	1.8%
Colorectal Cancer	4	0.0%
Depression	2,107	25.7%
Diabetes	278	3.4%
Endometrial Cancer	1	0.0%
Glaucoma	51	0.6%
Heart Failure	20	0.2%
Hip / Pelvic Fracture	3	0.0%
Hyperlipidemia	832	10.2%
Hypertension	1,138	13.9%
Ischemic Heart Disease	67	0.8%
Lung Cancer	0	0.0%
Osteoporosis	19	0.2%
Prostate Cancer	6	0.1%
Rheumatoid Arthritis / Osteoarthritis	543	6.6%
Stroke / Transient Ischemic Attack	23	0.3%

Table 1e: Baseline table (NorthstarRx Mixed Amphetamine Salt, 7 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.5
Mean number of filled prescriptions	13.6	11.3
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1f: Baseline table (NorthstarRx Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	8,149	
Demographics		
Mean Age (years)	34.7	13.7
Age (years): 00-01	0	0.0%
Age (years): 02-04	5	0.1%
Age (years): 05-09	202	2.5%
Age (years): 10-14	405	5.0%
Age (years): 15-18	409	5.0%
Age (years): 19-21	492	6.0%
Age (years): 22-44	4,688	57.5%
Age (years): 45-64	1,914	23.5%
Age (years): 65-74	30	0.4%
Age (years): 75+	4	0.0%
Sex (Female)	4,137	50.8%
Sex (Male)	4,012	49.2%
Year (2013)	0	0.0%
Year (2014)	0	0.0%
Year (2015)	0	0.0%
Year (2016)	0	0.0%
Year (2017)	0	0.0%
Year (2018)	4,466	54.8%
Year (2019)	3,683	45.2%
Recorded history of:		
Prior combined comorbidity score ³	0.4	0.9
Acquired Hypothyroidism	469	5.8%
Acute Myocardial Infarction	4	0.0%
Alzheimer's Disease	1	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	11	0.1%
Anemia	242	3.0%
Asthma	384	4.7%
Atrial Fibrillation	16	0.2%
Benign Prostatic Hyperplasia	52	0.6%
Breast Cancer	27	0.3%
Cataracts	68	0.8%
Chronic Kidney Disease	183	2.2%
Chronic Obstructive Pulmonary Disease	145	1.8%
Colorectal Cancer	4	0.0%
Depression	2,099	25.8%
Diabetes	276	3.4%
Endometrial Cancer	1	0.0%
Glaucoma	51	0.6%
Heart Failure	20	0.2%
Hip / Pelvic Fracture	3	0.0%
Hyperlipidemia	829	10.2%
Hypertension	1,135	13.9%
Ischemic Heart Disease	66	0.8%
Lung Cancer	0	0.0%
Osteoporosis	18	0.2%
Prostate Cancer	6	0.1%
Rheumatoid Arthritis / Osteoarthritis	541	6.6%
Stroke / Transient Ischemic Attack	23	0.3%

Table 1f: Baseline table (NorthstarRx Mixed Amphetamine Salt, 14 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.5
Mean number of filled prescriptions	13.6	11.3
Mean number of generics	4.7	3.8
Mean number of unique drug classes	4.5	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1g: Baseline table (Sandoz Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	99,417	
Demographics		
Mean Age (years)	32.0	13.6
Age (years): 00-01	0	0.0%
Age (years): 02-04	155	0.2%
Age (years): 05-09	3,896	3.9%
Age (years): 10-14	5,685	5.7%
Age (years): 15-18	5,967	6.0%
Age (years): 19-21	8,261	8.3%
Age (years): 22-44	56,654	57.0%
Age (years): 45-64	18,326	18.4%
Age (years): 65-74	437	0.4%
Age (years): 75+	36	0.0%
Sex (Female)	51,634	51.9%
Sex (Male)	47,783	48.1%
Year (2013)	23,174	23.3%
Year (2014)	15,676	15.8%
Year (2015)	7,556	7.6%
Year (2016)	7,125	7.2%
Year (2017)	13,350	13.4%
Year (2018)	26,167	26.3%
Year (2019)	6,369	6.4%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	4,874	4.9%
Acute Myocardial Infarction	37	0.0%
Alzheimer's Disease	7	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	120	0.1%
Anemia	2,850	2.9%
Asthma	4,967	5.0%
Atrial Fibrillation	149	0.1%
Benign Prostatic Hyperplasia	492	0.5%
Breast Cancer	354	0.4%
Cataracts	642	0.6%
Chronic Kidney Disease	1,272	1.3%
Chronic Obstructive Pulmonary Disease	1,647	1.7%
Colorectal Cancer	68	0.1%
Depression	21,868	22.0%
Diabetes	2,595	2.6%
Endometrial Cancer	19	0.0%
Glaucoma	592	0.6%
Heart Failure	180	0.2%
Hip / Pelvic Fracture	49	0.0%
Hyperlipidemia	8,451	8.5%
Hypertension	9,720	9.8%
Ischemic Heart Disease	565	0.6%
Lung Cancer	22	0.0%
Osteoporosis	325	0.3%
Prostate Cancer	70	0.1%
Rheumatoid Arthritis / Osteoarthritis	5,141	5.2%
Stroke / Transient Ischemic Attack	244	0.2%

Table 1g: Baseline table (Sandoz Mixed Amphetamine Salt, 0 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.7
Mean number of filled prescriptions	13.9	11.3
Mean number of generics	4.9	3.9
Mean number of unique drug classes	4.7	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1h: Baseline table (Sandoz Mixed Amphetamine Salt, 7 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	97,631	
Demographics		
Mean Age (years)	32.0	13.6
Age (years): 00-01	0	0.0%
Age (years): 02-04	152	0.2%
Age (years): 05-09	3,835	3.9%
Age (years): 10-14	5,608	5.7%
Age (years): 15-18	5,921	6.1%
Age (years): 19-21	8,132	8.3%
Age (years): 22-44	55,593	56.9%
Age (years): 45-64	17,934	18.4%
Age (years): 65-74	423	0.4%
Age (years): 75+	33	0.0%
Sex (Female)	50,705	51.9%
Sex (Male)	46,926	48.1%
Year (2013)	22,223	22.8%
Year (2014)	15,506	15.9%
Year (2015)	7,384	7.6%
Year (2016)	7,027	7.2%
Year (2017)	13,166	13.5%
Year (2018)	26,009	26.6%
Year (2019)	6,316	6.5%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	4,791	4.9%
Acute Myocardial Infarction	36	0.0%
Alzheimer's Disease	7	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	116	0.1%
Anemia	2,803	2.9%
Asthma	4,889	5.0%
Atrial Fibrillation	150	0.2%
Benign Prostatic Hyperplasia	476	0.5%
Breast Cancer	349	0.4%
Cataracts	626	0.6%
Chronic Kidney Disease	1,245	1.3%
Chronic Obstructive Pulmonary Disease	1,601	1.6%
Colorectal Cancer	68	0.1%
Depression	21,465	22.0%
Diabetes	2,550	2.6%
Endometrial Cancer	19	0.0%
Glaucoma	581	0.6%
Heart Failure	179	0.2%
Hip / Pelvic Fracture	46	0.0%
Hyperlipidemia	8,298	8.5%
Hypertension	9,496	9.7%
Ischemic Heart Disease	542	0.6%
Lung Cancer	20	0.0%
Osteoporosis	322	0.3%
Prostate Cancer	67	0.1%
Rheumatoid Arthritis / Osteoarthritis	5,037	5.2%
Stroke / Transient Ischemic Attack	245	0.3%

Table 1h: Baseline table (Sandoz Mixed Amphetamine Salt, 7 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.7
Mean number of filled prescriptions	13.9	11.3
Mean number of generics	4.9	3.9
Mean number of unique drug classes	4.7	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1: Baseline table (Sandoz Mixed Amphetamine Salt, 14 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	96,516	
Demographics		
Mean Age (years)	32.0	13.6
Age (years): 00-01	0	0.0%
Age (years): 02-04	150	0.2%
Age (years): 05-09	3,798	3.9%
Age (years): 10-14	5,557	5.8%
Age (years): 15-18	5,878	6.1%
Age (years): 19-21	8,051	8.3%
Age (years): 22-44	54,922	56.9%
Age (years): 45-64	17,710	18.3%
Age (years): 65-74	419	0.4%
Age (years): 75+	31	0.0%
Sex (Female)	50,115	51.9%
Sex (Male)	46,401	48.1%
Year (2013)	21,629	22.4%
Year (2014)	15,343	15.9%
Year (2015)	7,294	7.6%
Year (2016)	6,995	7.2%
Year (2017)	13,037	13.5%
Year (2018)	25,916	26.9%
Year (2019)	6,302	6.5%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	4,735	4.9%
Acute Myocardial Infarction	36	0.0%
Alzheimer's Disease	7	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	116	0.1%
Anemia	2,770	2.9%
Asthma	4,839	5.0%
Atrial Fibrillation	148	0.2%
Benign Prostatic Hyperplasia	473	0.5%
Breast Cancer	348	0.4%
Cataracts	617	0.6%
Chronic Kidney Disease	1,227	1.3%
Chronic Obstructive Pulmonary Disease	1,571	1.6%
Colorectal Cancer	68	0.1%
Depression	21,225	22.0%
Diabetes	2,520	2.6%
Endometrial Cancer	19	0.0%
Glaucoma	569	0.6%
Heart Failure	177	0.2%
Hip / Pelvic Fracture	47	0.0%
Hyperlipidemia	8,164	8.5%
Hypertension	9,370	9.7%
Ischemic Heart Disease	530	0.5%
Lung Cancer	20	0.0%
Osteoporosis	314	0.3%
Prostate Cancer	66	0.1%
Rheumatoid Arthritis / Osteoarthritis	4,981	5.2%
Stroke / Transient Ischemic Attack	243	0.3%

Table 1i: Baseline table (Sandoz Mixed Amphetamine Salt, 14 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.8	7.4
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.7
Mean number of filled prescriptions	13.9	11.3
Mean number of generics	4.9	3.9
Mean number of unique drug classes	4.7	3.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)

Table 1j: Baseline table (SpecGx Mixed Amphetamine Salt, 0 Day Gap)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	37,726	
Demographics		
Mean Age (years)	34.8	13.0
Age (years): 00-01	0	0.0%
Age (years): 02-04	6	0.0%
Age (years): 05-09	505	1.3%
Age (years): 10-14	1,323	3.5%
Age (years): 15-18	1,708	4.5%
Age (years): 19-21	2,557	6.8%
Age (years): 22-44	22,922	60.8%
Age (years): 45-64	8,498	22.5%
Age (years): 65-74	190	0.5%
Age (years): 75+	17	0.0%
Sex (Female)	19,977	53.0%
Sex (Male)	17,749	47.0%
Year (2013)	2	0.0%
Year (2014)	9,214	24.4%
Year (2015)	2,513	6.7%
Year (2016)	2,018	5.3%
Year (2017)	6,663	17.7%
Year (2018)	12,691	33.6%
Year (2019)	4,625	12.3%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.8
Acquired Hypothyroidism	2,136	5.7%
Acute Myocardial Infarction	18	0.0%
Alzheimer's Disease	5	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	46	0.1%
Anemia	1,185	3.1%
Asthma	1,799	4.8%
Atrial Fibrillation	71	0.2%
Benign Prostatic Hyperplasia	237	0.6%
Breast Cancer	152	0.4%
Cataracts	295	0.8%
Chronic Kidney Disease	601	1.6%
Chronic Obstructive Pulmonary Disease	703	1.9%
Colorectal Cancer	36	0.1%
Depression	9,013	23.9%
Diabetes	1,242	3.3%
Endometrial Cancer	7	0.0%
Glaucoma	212	0.6%
Heart Failure	67	0.2%
Hip / Pelvic Fracture	24	0.1%
Hyperlipidemia	3,746	9.9%
Hypertension	4,670	12.4%
Ischemic Heart Disease	252	0.7%
Lung Cancer	10	0.0%
Osteoporosis	110	0.3%
Prostate Cancer	46	0.1%
Rheumatoid Arthritis / Osteoarthritis	2,364	6.3%
Stroke / Transient Ischemic Attack	83	0.2%

Table 1j: Baseline table (SpecGx Mixed Amphetamine Salt, 0 Day Gap)

Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	6.6	7.1
Mean number of emergency room encounters (ED)	0.2	0.6
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	0.8	2.4
Mean number of filled prescriptions	14.8	11.8
Mean number of generics	5.0	4.0
Mean number of unique drug classes	4.8	3.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Charlson/Elixhauser Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759)



Table 2a: Descriptive statistics of cumulative exposure duration, all episodes, in days								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	71.85	81.06	1	30	30	90	600
Barr Mixed Amphetamine Salt, 7 Day Gap	828	81.31	83.86	1	37	37	97	629
Barr Mixed Amphetamine Salt, 14 Day Gap	822	90.36	88.36	1	44	44	104	700
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	55.92	37.28	1	30	40	80	181
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	62.81	39.59	1	37	42	89	182
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	68.03	40.85	1	44	45	94	182
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	102.60	147.47	1	30	60	118	2,146
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	113.95	154.16	1	37	67	122	2,153
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	124.22	159.91	1	44	74	132	2,156
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	66.87	82.61	1	30	30	60	1,536

Table 2b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	71.85	81.06	1	30	30	90	600
Female	400	73.61	87.46	3	30	30	90	600
Male	440	70.25	74.82	1	30	30	90	570
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	828	81.31	83.86	1	37	37	97	629
Female	394	82.28	87.37	3	37	37	97	629
Male	434	80.43	80.63	1	37	37	97	577
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	822	90.36	88.36	1	44	44	104	700
Female	389	91.05	91.32	3	44	44	104	700
Male	433	89.73	85.71	1	44	44	104	584
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	55.92	37.28	1	30	40	80	181
Female	4,219	56.03	37.36	1	30	40	81	180
Male	4,073	55.79	37.21	1	30	40	79	181
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	62.81	39.59	1	37	42	89	182
Female	4,161	63.01	39.72	1	37	43	90	182
Male	4,029	62.60	39.47	1	37	42	87	182
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	68.03	40.85	1	44	45	94	182
Female	4,137	68.29	41.00	1	44	46	96	182
Male	4,012	67.76	40.71	1	44	45	93	182
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	102.60	147.47	1	30	60	118	2,146
Female	51,634	103.31	149.44	1	30	60	118	2,146
Male	47,783	101.83	145.30	1	30	60	117	2,134
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	113.95	154.16	1	37	67	122	2,153
Female	50,705	115.02	157.14	1	37	67	122	2,153
Male	46,926	112.79	150.86	1	37	67	122	1,984
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	124.22	159.91	1	44	74	132	2,156
Female	50,115	125.39	163.20	1	44	74	132	2,156
Male	46,401	122.96	156.28	1	44	74	132	2,031
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	66.87	82.61	1	30	30	60	1,536
Female	19,977	65.69	80.49	1	30	30	60	1,510



Table 2b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Male	17,749	68.19	84.91	1	30	30	67	1,536
Other	0	-	-	-	-	-	-	-

Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	71.85	81.06	1	30	30	90	600
00-01	0	-	-	-	-	-	-	-
02-04	4	179.50	187.30	30	30	135	329	418
05-09	105	72.48	85.17	7	30	30	83	570
10-14	134	71.75	70.11	1	30	60	90	475
15-18	90	69.86	82.44	15	30	30	90	565
19-21	83	64.51	62.83	7	30	30	90	330
22-44	312	67.77	73.23	3	30	30	90	570
45-64	106	88.65	111.62	15	30	30	90	600
65-74	6	38.33	14.29	27	30	30	53	60
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	828	81.31	83.86	1	37	37	97	629
00-01	0	-	-	-	-	-	-	-
02-04	4	196.00	195.42	37	37	155	355	437
05-09	104	84.25	91.15	14	37	37	97	577
10-14	131	83.20	76.79	1	37	69	97	527
15-18	88	74.95	71.72	17	37	37	85	388
19-21	83	75.93	73.38	14	37	37	97	428
22-44	308	77.69	78.30	3	37	37	97	488
45-64	104	94.04	108.71	15	37	37	107	629
65-74	6	45.33	17.78	27	37	37	60	74
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	822	90.36	88.36	1	44	44	104	700
00-01	0	-	-	-	-	-	-	-
02-04	4	206.00	195.36	44	44	172	368	437
05-09	103	91.74	93.60	14	44	44	104	584
10-14	130	94.70	83.87	1	44	75	104	562
15-18	88	85.24	78.85	17	44	44	92	416
19-21	83	85.45	77.27	21	44	44	104	435
22-44	305	85.95	80.97	3	44	44	104	520
45-64	103	102.58	116.22	15	44	44	118	700
65-74	6	52.33	21.62	27	44	44	67	88
75+	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	55.92	37.28	1	30	40	80	181
00-01	0	-	-	-	-	-	-	-
02-04	5	59.80	36.75	30	30	59	60	120
05-09	202	60.09	37.75	3	30	54	87	152
10-14	409	57.73	37.27	1	30	51	86	168

Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
15-18	412	48.74	33.84	3	30	30	60	179
19-21	497	54.03	36.88	2	30	33	72	178
22-44	4,772	55.54	37.11	1	30	39	78	181
45-64	1,960	58.05	38.22	1	30	45	87	180
65-74	31	45.65	34.44	1	27	30	60	144
75+	4	107.50	28.72	90	90	95	125	150
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	62.81	39.59	1	37	42	89	182
00-01	0	-	-	-	-	-	-	-
02-04	5	68.60	39.88	37	37	61	74	134
05-09	202	67.16	40.12	3	37	54	94	163
10-14	406	65.04	39.77	1	37	57	95	169
15-18	409	55.48	36.19	3	37	37	74	179
19-21	493	61.20	39.14	2	37	39	79	182
22-44	4,717	62.22	39.29	1	37	41	86	182
45-64	1,924	65.36	40.77	1	37	49	97	180
65-74	30	50.40	37.01	1	27	39	67	146
75+	4	115.00	23.85	97	101	107	130	150
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	68.03	40.85	1	44	45	94	182
00-01	0	-	-	-	-	-	-	-
02-04	5	76.00	44.04	41	44	61	86	148
05-09	202	72.42	40.74	3	44	55	100	165
10-14	405	70.38	41.06	1	44	62	102	174
15-18	409	60.67	37.41	3	39	44	85	179
19-21	492	66.38	40.57	2	44	44	88	182
22-44	4,688	67.39	40.52	1	44	44	92	182
45-64	1,914	70.72	42.13	1	44	52	103	182
65-74	30	53.63	38.74	1	27	44	70	146
75+	4	121.00	20.03	104	109	115	133	150
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	102.60	147.47	1	30	60	118	2,146
00-01	0	-	-	-	-	-	-	-
02-04	155	90.15	119.46	1	30	30	90	655
05-09	3,896	87.60	114.79	1	30	43	90	1,232
10-14	5,685	90.48	122.45	1	30	50	90	1,440
15-18	5,967	92.21	132.23	1	30	48	90	1,670
19-21	8,261	99.63	140.31	1	30	60	112	2,013
22-44	56,654	101.66	144.43	1	30	60	116	2,146
45-64	18,326	116.79	173.99	1	30	60	120	2,070
65-74	437	125.79	173.55	1	30	60	150	1,425



Table 2c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
75+	36	72.81	65.38	28	30	30	93	270
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	113.95	154.16	1	37	67	122	2,153
00-01	0	-	-	-	-	-	-	-
02-04	152	98.66	124.44	1	37	37	105	741
05-09	3,835	99.44	123.30	1	37	46	110	1,232
10-14	5,608	102.61	130.43	1	37	55	111	1,457
15-18	5,921	104.73	140.47	1	37	55	111	1,745
19-21	8,132	112.42	148.93	1	37	67	121	2,020
22-44	55,593	112.59	150.14	1	37	67	121	2,153
45-64	17,934	128.34	181.99	1	37	70	138	2,085
65-74	423	131.58	179.47	1	37	68	148	1,473
75+	33	72.85	57.59	35	37	37	97	233
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	124.22	159.91	1	44	74	132	2,156
00-01	0	-	-	-	-	-	-	-
02-04	150	107.67	130.26	1	44	44	118	783
05-09	3,798	109.71	129.45	1	44	51	122	1,240
10-14	5,557	112.96	135.88	1	44	59	132	1,479
15-18	5,878	116.51	148.89	1	44	58	132	1,803
19-21	8,051	123.70	156.54	1	44	74	132	2,027
22-44	54,922	122.54	155.40	1	44	74	132	2,156
45-64	17,710	138.63	187.49	1	44	76	148	2,099
65-74	419	143.53	200.87	1	44	74	162	1,879
75+	31	78.65	57.18	42	44	44	104	255
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	66.87	82.61	1	30	30	60	1,536
00-01	0	-	-	-	-	-	-	-
02-04	6	70.00	36.33	30	30	75	90	120
05-09	505	75.94	103.10	1	30	30	90	935
10-14	1,323	70.56	82.43	2	30	30	80	867
15-18	1,708	66.03	80.24	1	30	30	60	1,063
19-21	2,557	62.82	72.62	1	30	30	60	808
22-44	22,922	64.89	79.37	1	30	30	60	1,536
45-64	8,498	72.00	91.12	1	30	30	90	1,240
65-74	190	87.12	128.04	2	30	30	90	900
75+	17	75.35	71.62	12	30	49	90	292



Table 3a: Descriptive statistics of first exposure episode duration, in days								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	37.98	31.63	1	30	30	30	570
Barr Mixed Amphetamine Salt, 7 Day Gap	828	50.11	42.62	1	37	37	37	577
Barr Mixed Amphetamine Salt, 14 Day Gap	822	59.54	45.69	1	44	44	57	584
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	37.04	24.13	1	30	30	30	180
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	51.58	34.09	1	37	37	67	182
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	59.25	36.45	1	44	44	75	182
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	40.00	47.18	1	30	30	30	1,920
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	55.30	62.42	1	37	37	43	1,927
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	66.50	72.06	1	44	44	74	2,156
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	35.69	26.77	1	30	30	30	870

Table 3b: Descriptive statistics of first exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	37.98	31.63	1	30	30	30	570
Female	400	37.43	30.35	3	30	30	30	443
Male	440	38.48	32.78	1	30	30	30	570
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	828	50.11	42.62	1	37	37	37	577
Female	394	49.48	41.25	3	37	37	37	443
Male	434	50.69	43.86	1	37	37	37	577
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	822	59.54	45.69	1	44	44	57	584
Female	389	57.94	39.91	3	44	44	44	383
Male	433	60.99	50.32	1	44	44	59	584
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	37.04	24.13	1	30	30	30	180
Female	4,219	36.99	24.26	1	30	30	30	180
Male	4,073	37.08	24.01	1	30	30	30	174
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	51.58	34.09	1	37	37	67	182
Female	4,161	51.68	34.15	1	37	37	67	182
Male	4,029	51.48	34.03	1	37	37	67	182
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	59.25	36.45	1	44	44	75	182
Female	4,137	59.29	36.41	1	44	44	75	182
Male	4,012	59.20	36.50	1	44	44	75	182
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	40.00	47.18	1	30	30	30	1,920
Female	51,634	39.75	46.54	1	30	30	30	1,753
Male	47,783	40.27	47.86	1	30	30	30	1,920
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	55.30	62.42	1	37	37	43	1,927
Female	50,705	54.99	62.32	1	37	37	38	1,760
Male	46,926	55.63	62.53	1	37	37	48	1,927
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	66.50	72.06	1	44	44	74	2,156
Female	50,115	66.26	72.77	1	44	44	74	2,156
Male	46,401	66.75	71.28	1	44	44	74	1,992
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	35.69	26.77	1	30	30	30	870
Female	19,977	35.61	27.78	1	30	30	30	870



Table 3b: Descriptive statistics of first exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Male	17,749	35.79	25.58	1	30	30	30	540
Other	0	-	-	-	-	-	-	-

Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	840	37.98	31.63	1	30	30	30	570
00-01	0	-	-	-	-	-	-	-
02-04	4	45.00	30.00	30	30	30	60	90
05-09	105	39.25	54.75	4	30	30	30	570
10-14	134	35.25	19.33	1	30	30	30	114
15-18	90	38.81	21.66	15	30	30	30	120
19-21	83	41.55	26.99	7	30	30	30	155
22-44	312	35.97	21.15	3	30	30	30	180
45-64	106	42.76	46.63	15	30	30	30	443
65-74	6	29.50	1.22	27	30	30	30	30
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	828	50.11	42.62	1	37	37	37	577
00-01	0	-	-	-	-	-	-	-
02-04	4	137.00	200.00	37	37	37	237	437
05-09	104	52.15	61.65	11	37	37	37	577
10-14	131	46.17	30.39	1	37	37	37	284
15-18	88	47.47	25.84	17	37	37	37	190
19-21	83	55.53	49.84	14	37	37	37	328
22-44	308	49.22	37.88	3	37	37	37	443
45-64	104	51.11	35.63	15	37	37	39	261
65-74	6	35.33	4.08	27	37	37	37	37
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	822	59.54	45.69	1	44	44	57	584
00-01	0	-	-	-	-	-	-	-
02-04	4	142.25	196.50	44	44	44	241	437
05-09	103	66.09	76.43	14	44	44	59	584
10-14	130	56.47	32.89	1	44	44	66	291
15-18	88	54.58	26.80	17	44	44	44	197
19-21	83	63.81	49.79	21	44	44	74	335
22-44	305	57.86	37.96	3	44	44	44	383
45-64	103	60.52	34.12	15	44	44	74	194
65-74	6	41.17	6.94	27	44	44	44	44
75+	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	37.04	24.13	1	30	30	30	180
00-01	0	-	-	-	-	-	-	-
02-04	5	42.00	26.83	30	30	30	30	90
05-09	202	37.77	24.63	3	30	30	30	152
10-14	409	35.73	22.99	1	30	30	30	168



Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
15-18	412	34.59	22.98	3	30	30	30	179
19-21	497	35.39	23.48	2	30	30	30	175
22-44	4,772	37.28	24.31	1	30	30	30	178
45-64	1,960	37.49	24.12	1	30	30	30	180
65-74	31	34.71	24.92	1	27	30	41	120
75+	4	82.50	51.23	30	45	75	120	150
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	51.58	34.09	1	37	37	67	182
00-01	0	-	-	-	-	-	-	-
02-04	5	53.80	26.29	37	37	37	61	97
05-09	202	53.40	34.83	3	37	37	67	162
10-14	406	51.94	35.62	1	37	37	68	169
15-18	409	45.97	30.29	3	35	37	42	179
19-21	493	48.80	32.48	2	37	37	58	182
22-44	4,717	51.79	34.22	1	37	37	67	182
45-64	1,924	52.73	34.37	1	37	37	67	180
65-74	30	43.40	33.47	1	27	37	48	146
75+	4	87.75	48.19	37	52	82	124	150
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	59.25	36.45	1	44	44	75	182
00-01	0	-	-	-	-	-	-	-
02-04	5	67.20	27.25	41	44	61	86	104
05-09	202	63.02	37.54	3	44	44	84	165
10-14	405	59.78	37.15	1	44	44	79	174
15-18	409	53.40	32.97	3	38	44	61	179
19-21	492	56.85	35.01	2	44	44	74	182
22-44	4,688	59.20	36.48	1	44	44	75	182
45-64	1,914	60.78	37.05	1	44	44	76	182
65-74	30	49.77	35.43	1	27	44	68	146
75+	4	93.00	45.21	44	59	89	127	150
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	40.00	47.18	1	30	30	30	1,920
00-01	0	-	-	-	-	-	-	-
02-04	155	41.68	48.66	1	30	30	30	450
05-09	3,896	38.76	42.14	1	30	30	30	1,232
10-14	5,685	38.42	41.38	1	30	30	30	1,080
15-18	5,967	37.22	30.42	1	30	30	30	840
19-21	8,261	38.20	40.84	1	30	30	30	1,344
22-44	56,654	40.11	47.09	1	30	30	30	1,920
45-64	18,326	41.90	55.77	1	30	30	30	1,753
65-74	437	50.09	69.99	1	30	30	34	1,020



Table 3c: Descriptive statistics of first exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
75+	36	41.03	24.59	28	30	30	30	120
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	55.30	62.42	1	37	37	43	1,927
00-01	0	-	-	-	-	-	-	-
02-04	152	60.24	67.89	1	37	37	67	457
05-09	3,835	53.63	59.36	1	37	37	40	1,232
10-14	5,608	52.37	54.79	1	37	37	37	1,185
15-18	5,921	50.13	42.70	1	37	37	37	1,086
19-21	8,132	52.04	50.93	1	37	37	37	1,344
22-44	55,593	55.48	62.28	1	37	37	46	1,927
45-64	17,934	58.98	74.15	1	37	37	67	1,760
65-74	423	63.22	78.49	1	37	37	67	1,027
75+	33	47.24	22.92	35	37	37	37	107
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	66.50	72.06	1	44	44	74	2,156
00-01	0	-	-	-	-	-	-	-
02-04	150	72.64	74.17	1	44	44	75	464
05-09	3,798	65.21	65.40	1	44	44	74	1,232
10-14	5,557	63.07	59.70	1	44	44	74	927
15-18	5,878	60.73	52.84	1	44	44	54	1,134
19-21	8,051	63.16	59.57	1	44	44	74	1,344
22-44	54,922	66.40	70.84	1	44	44	74	2,156
45-64	17,710	71.21	87.43	1	44	44	74	1,992
65-74	419	81.06	133.85	1	44	44	83	1,879
75+	31	56.19	23.98	42	44	44	44	114
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	35.69	26.77	1	30	30	30	870
00-01	0	-	-	-	-	-	-	-
02-04	6	35.00	12.25	30	30	30	30	60
05-09	505	35.35	29.93	1	30	30	30	411
10-14	1,323	35.68	24.04	2	30	30	30	364
15-18	1,708	33.84	17.75	1	30	30	30	270
19-21	2,557	34.00	19.21	1	30	30	30	360
22-44	22,922	35.59	26.11	1	30	30	30	798
45-64	8,498	36.79	31.41	1	30	30	30	870
65-74	190	39.24	39.31	1	30	30	30	495
75+	17	37.00	21.96	12	30	30	30	90

Table 4a: Descriptive statistics of all exposure episode durations, in days								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	1,566	38.54	30.01	1	30	30	30	570
Barr Mixed Amphetamine Salt, 7 Day Gap	1,323	50.89	41.32	1	37	37	37	577
Barr Mixed Amphetamine Salt, 14 Day Gap	1,219	60.93	44.60	1	44	44	74	584
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	13,060	35.50	22.19	1	30	30	30	180
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	10,629	48.39	32.00	1	37	37	59	182
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	9,903	55.98	35.03	1	40	44	74	182
Sandoz Mixed Amphetamine Salt, 0 Day Gap	245,450	41.56	48.03	1	30	30	30	2,131
Sandoz Mixed Amphetamine Salt, 7 Day Gap	194,170	57.29	64.66	1	37	37	67	2,131
Sandoz Mixed Amphetamine Salt, 14 Day Gap	174,361	68.76	73.88	1	44	44	74	2,156
SpecGx Mixed Amphetamine Salt, 0 Day Gap	68,049	37.07	29.86	1	30	30	30	920

Table 4b: Descriptive statistics of all exposure episode durations, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	1,566	38.54	30.01	1	30	30	30	570
Female	780	37.75	28.80	2	30	30	30	443
Male	786	39.33	31.16	1	30	30	30	570
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	1,323	50.89	41.32	1	37	37	37	577
Female	653	49.64	40.00	2	37	37	37	443
Male	670	52.10	42.56	1	37	37	57	577
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	1,219	60.93	44.60	1	44	44	74	584
Female	596	59.43	40.73	2	44	44	62	383
Male	623	62.37	48.00	1	44	44	74	584
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	13,060	35.50	22.19	1	30	30	30	180
Female	6,694	35.32	22.14	1	30	30	30	180
Male	6,366	35.70	22.24	1	30	30	30	174
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	10,629	48.39	32.00	1	37	37	59	182
Female	5,422	48.35	32.02	1	35	37	60	182
Male	5,207	48.44	31.98	1	37	37	59	182
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	9,903	55.98	35.03	1	40	44	74	182
Female	5,051	55.94	35.01	1	39	44	74	182
Male	4,852	56.03	35.06	1	40	44	74	182
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 0 Day Gap	245,450	41.56	48.03	1	30	30	30	2,131
Female	129,262	41.27	47.65	1	30	30	30	2,131
Male	116,188	41.88	48.44	1	30	30	30	1,920
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 7 Day Gap	194,170	57.29	64.66	1	37	37	67	2,131
Female	102,259	57.03	64.72	1	37	37	67	2,131
Male	91,911	57.59	64.58	1	37	37	67	1,927
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 14 Day Gap	174,361	68.76	73.88	1	44	44	74	2,156
Female	91,571	68.62	74.26	1	44	44	74	2,156
Male	82,790	68.91	73.45	1	44	44	74	1,992
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 0 Day Gap	68,049	37.07	29.86	1	30	30	30	920
Female	35,598	36.86	29.86	1	30	30	30	870



Table 4b: Descriptive statistics of all exposure episode durations, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Male	32,451	37.30	29.86	1	30	30	30	920
Other	0	-	-	-	-	-	-	-

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	1,566	38.54	30.01	1	30	30	30	570
00-01	0	-	-	-	-	-	-	-
02-04	13	55.23	58.61	28	30	30	60	240
05-09	191	39.84	45.97	4	30	30	30	570
10-14	265	36.28	20.25	1	30	30	30	180
15-18	152	41.36	30.39	14	30	30	30	300
19-21	141	37.97	21.95	7	30	30	30	155
22-44	566	37.36	25.21	1	30	30	30	240
45-64	230	40.86	35.15	4	30	30	30	443
65-74	8	28.75	2.55	23	29	30	30	30
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	1,323	50.89	41.32	1	37	37	37	577
00-01	0	-	-	-	-	-	-	-
02-04	7	112.00	146.31	37	37	37	100	437
05-09	161	54.42	59.17	11	37	37	59	577
10-14	229	47.59	30.45	1	37	37	37	284
15-18	138	47.80	25.19	14	37	37	37	190
19-21	121	52.08	43.44	14	37	37	37	328
22-44	476	50.27	39.91	2	37	37	37	443
45-64	183	53.44	37.13	5	37	37	67	261
65-74	8	34.00	5.66	23	32	37	37	37
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	1,219	60.93	44.60	1	44	44	74	584
00-01	0	-	-	-	-	-	-	-
02-04	5	164.80	177.49	44	44	44	255	437
05-09	140	67.49	68.38	14	44	44	74	584
10-14	213	57.80	33.75	1	44	44	74	291
15-18	135	55.56	27.43	14	44	44	59	197
19-21	115	61.67	45.60	21	44	44	44	335
22-44	442	59.31	39.94	2	44	44	67	383
45-64	161	65.63	42.49	5	44	44	78	260
65-74	8	39.25	8.86	23	36	44	44	44
75+	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	13,060	35.50	22.19	1	30	30	30	180
00-01	0	-	-	-	-	-	-	-
02-04	8	37.38	21.27	29	30	30	30	90
05-09	346	35.08	22.27	2	30	30	30	152
10-14	683	34.57	21.43	1	30	30	30	168

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
15-18	611	32.87	21.07	1	30	30	30	179
19-21	794	33.82	21.94	1	30	30	30	175
22-44	7,409	35.77	22.41	1	30	30	30	178
45-64	3,162	35.98	21.93	1	30	30	30	180
65-74	40	35.38	23.79	1	26	30	44	120
75+	7	61.43	47.06	10	30	60	90	150
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	10,629	48.39	32.00	1	37	37	59	182
00-01	0	-	-	-	-	-	-	-
02-04	7	49.00	22.98	37	37	37	61	97
05-09	279	48.63	32.18	2	37	37	55	162
10-14	554	47.67	32.99	1	37	37	56	169
15-18	522	43.47	28.53	1	33	37	37	179
19-21	660	45.71	30.32	2	36	37	41	182
22-44	6,038	48.61	32.22	1	35	37	59	182
45-64	2,527	49.76	32.21	1	37	37	67	180
65-74	36	42.00	30.89	1	26	37	48	146
75+	6	76.67	41.84	37	42	67	97	150
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	9,903	55.98	35.03	1	40	44	74	182
00-01	0	-	-	-	-	-	-	-
02-04	6	63.33	26.15	41	44	53	86	104
05-09	251	58.28	36.20	2	44	44	76	165
10-14	515	55.34	35.39	1	37	44	74	174
15-18	487	50.96	31.58	3	35	44	53	179
19-21	597	54.71	33.49	2	41	44	70	182
22-44	5,651	55.91	35.16	1	39	44	74	182
45-64	2,357	57.43	35.48	1	41	44	74	182
65-74	33	48.76	34.01	1	27	44	67	146
75+	6	80.67	40.86	42	44	72	104	150
Sandoz Mixed Amphetamine Salt, 0 Day Gap	245,450	41.56	48.03	1	30	30	30	2,131
00-01	0	-	-	-	-	-	-	-
02-04	304	45.97	55.71	1	30	30	30	450
05-09	8,574	39.81	40.40	1	30	30	30	1,232
10-14	13,072	39.35	40.01	1	30	30	30	1,080
15-18	13,934	39.49	40.67	1	30	30	30	1,100
19-21	20,502	40.14	44.21	1	30	30	30	1,953
22-44	138,299	41.65	48.25	1	30	30	30	2,131
45-64	49,514	43.23	53.38	1	30	30	30	1,753
65-74	1,184	46.43	55.69	1	30	30	30	1,020

Table 4c: Descriptive statistics of all exposure episode durations, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
75+	67	39.12	23.03	5	30	30	30	120
Sandoz Mixed Amphetamine Salt, 7 Day Gap	194,170	57.29	64.66	1	37	37	67	2,131
00-01	0	-	-	-	-	-	-	-
02-04	232	64.64	71.29	1	37	37	68	457
05-09	6,987	54.58	56.65	1	37	37	57	1,232
10-14	10,868	52.95	52.61	1	37	37	37	1,185
15-18	11,700	53.00	52.93	1	37	37	37	1,107
19-21	16,678	54.81	58.66	1	37	37	53	1,953
22-44	108,942	57.45	64.60	1	37	37	67	2,131
45-64	37,831	60.84	74.02	1	37	37	67	1,760
65-74	883	63.03	74.18	1	37	37	67	1,027
75+	49	49.06	30.99	5	37	37	37	196
Sandoz Mixed Amphetamine Salt, 14 Day Gap	174,361	68.76	73.88	1	44	44	74	2,156
00-01	0	-	-	-	-	-	-	-
02-04	209	77.28	85.57	1	44	44	78	653
05-09	6,261	66.55	63.76	1	44	44	74	1,232
10-14	9,800	64.05	60.36	1	44	44	74	1,435
15-18	10,693	64.05	61.19	1	44	44	74	1,134
19-21	15,011	66.35	67.15	1	44	44	74	1,953
22-44	98,041	68.65	73.40	1	44	44	74	2,156
45-64	33,533	73.22	84.97	1	44	44	76	1,992
65-74	768	78.31	111.36	1	44	44	79	1,879
75+	45	54.18	24.10	5	44	44	44	114
SpecGx Mixed Amphetamine Salt, 0 Day Gap	68,049	37.07	29.86	1	30	30	30	920
00-01	0	-	-	-	-	-	-	-
02-04	12	35.00	11.68	30	30	30	30	60
05-09	976	39.29	38.48	1	30	30	30	480
10-14	2,547	36.65	26.82	2	30	30	30	510
15-18	3,166	35.62	23.36	1	30	30	30	390
19-21	4,517	35.56	24.81	1	30	30	30	573
22-44	40,238	36.96	29.59	1	30	30	30	920
45-64	16,176	37.83	32.14	1	30	30	30	870
65-74	387	42.77	47.51	1	30	30	30	495
75+	30	42.70	25.89	12	30	30	60	112

Table 5a: Descriptive statistics of days supplied per dispensing								
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	1,889	31.95	13.50	1	30	30	30	120
Barr Mixed Amphetamine Salt, 7 Day Gap	1,802	32.08	13.76	1	30	30	30	120
Barr Mixed Amphetamine Salt, 14 Day Gap	1,759	32.15	13.90	1	30	30	30	120
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	16,704	27.76	8.63	1	30	30	30	154
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	16,516	27.78	8.63	1	30	30	30	154
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	16,446	27.79	8.64	1	30	30	30	154
Sandoz Mixed Amphetamine Salt, 0 Day Gap	329,472	30.96	11.65	1	30	30	30	750
Sandoz Mixed Amphetamine Salt, 7 Day Gap	315,220	30.94	11.66	1	30	30	30	750
Sandoz Mixed Amphetamine Salt, 14 Day Gap	307,531	30.91	11.62	1	30	30	30	750
SpecGx Mixed Amphetamine Salt, 0 Day Gap	84,131	29.98	8.88	1	30	30	30	195

Table 5b: Descriptive statistics of days supplied per dispensing, by sex									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Barr Mixed Amphetamine Salt, 0 Day Gap	1,889	31.95	13.50	1	30	30	30	120	
Female	949	31.03	11.28	2	30	30	30	90	
Male	940	32.88	15.37	1	30	30	30	120	
Other	0	-	-	-	-	-	-	-	
Barr Mixed Amphetamine Salt, 7 Day Gap	1,802	32.08	13.76	1	30	30	30	120	
Female	892	31.10	11.55	2	30	30	30	90	
Male	910	33.04	15.57	1	30	30	30	120	
Other	0	-	-	-	-	-	-	-	
Barr Mixed Amphetamine Salt, 14 Day Gap	1,759	32.15	13.90	1	30	30	30	120	
Female	858	31.17	11.75	2	30	30	30	90	
Male	901	33.08	15.64	1	30	30	30	120	
Other	0	-	-	-	-	-	-	-	
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	16,704	27.76	8.63	1	30	30	30	154	
Female	8,511	27.78	8.80	1	30	30	30	154	
Male	8,193	27.74	8.46	1	30	30	30	90	
Other	0	-	-	-	-	-	-	-	
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	16,516	27.78	8.63	1	30	30	30	154	
Female	8,404	27.81	8.80	1	30	30	30	154	
Male	8,112	27.75	8.46	1	30	30	30	90	
Other	0	-	-	-	-	-	-	-	
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	16,446	27.79	8.64	1	30	30	30	154	
Female	8,366	27.81	8.81	1	30	30	30	154	
Male	8,080	27.76	8.46	1	30	30	30	90	
Other	0	-	-	-	-	-	-	-	
Sandoz Mixed Amphetamine Salt, 0 Day Gap	329,472	30.96	11.65	1	30	30	30	750	
Female	172,689	30.89	11.37	1	30	30	30	270	
Male	156,783	31.04	11.96	1	30	30	30	750	
Other	0	-	-	-	-	-	-	-	
Sandoz Mixed Amphetamine Salt, 7 Day Gap	315,220	30.94	11.66	1	30	30	30	750	
Female	165,469	30.87	11.39	1	30	30	30	270	
Male	149,751	31.01	11.96	1	30	30	30	750	
Other	0	-	-	-	-	-	-	-	
Sandoz Mixed Amphetamine Salt, 14 Day Gap	307,531	30.91	11.62	1	30	30	30	750	
Female	161,341	30.85	11.34	1	30	30	30	270	
Male	146,190	30.98	11.92	1	30	30	30	750	
Other	0	-	-	-	-	-	-	-	
SpecGx Mixed Amphetamine Salt, 0 Day Gap	84,131	29.98	8.88	1	30	30	30	195	
Female	43,709	30.02	8.99	1	30	30	30	195	



Table 5b: Descriptive statistics of days supplied per dispensing, by sex								
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
Male	40,422	29.94	8.77	1	30	30	30	120
Other	0	-	-	-	-	-	-	-

Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Barr Mixed Amphetamine Salt, 0 Day Gap	1,889	31.95	13.50	1	30	30	30	120	
00-01	0	-	-	-	-	-	-	-	-
02-04	24	29.92	0.41	28	30	30	30	30	30
05-09	232	32.80	15.63	4	30	30	30	120	
10-14	308	31.22	13.22	1	30	30	30	90	
15-18	179	35.12	17.35	14	30	30	30	90	
19-21	158	33.89	16.81	7	30	30	30	90	
22-44	693	30.51	10.58	1	30	30	30	90	
45-64	287	32.74	13.74	4	30	30	30	90	
65-74	8	28.75	2.55	23	29	30	30	30	
75+	0	-	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	1,802	32.08	13.76	1	30	30	30	120	
00-01	0	-	-	-	-	-	-	-	-
02-04	24	29.92	0.41	28	30	30	30	30	30
05-09	231	32.81	15.66	4	30	30	30	120	
10-14	296	31.38	13.42	1	30	30	30	90	
15-18	160	35.20	18.00	14	30	30	30	90	
19-21	159	34.21	16.96	7	30	30	30	90	
22-44	670	30.58	10.71	1	30	30	30	90	
45-64	254	33.22	14.47	4	30	30	30	90	
65-74	8	28.75	2.55	23	29	30	30	30	
75+	0	-	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	1,759	32.15	13.90	1	30	30	30	120	
00-01	0	-	-	-	-	-	-	-	-
02-04	24	29.92	0.41	28	30	30	30	30	30
05-09	223	32.95	15.92	4	30	30	30	120	
10-14	294	31.48	13.38	1	30	30	30	90	
15-18	160	35.20	18.00	14	30	30	30	90	
19-21	159	34.21	16.96	7	30	30	30	90	
22-44	647	30.60	10.90	1	30	30	30	90	
45-64	244	33.35	14.75	4	30	30	30	90	
65-74	8	28.75	2.55	23	29	30	30	30	
75+	0	-	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	16,704	27.76	8.63	1	30	30	30	154	
00-01	0	-	-	-	-	-	-	-	-
02-04	11	27.18	6.59	10	30	30	30	30	30
05-09	438	27.71	8.72	1	30	30	30	90	
10-14	852	27.71	8.98	1	30	30	30	90	

Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)								
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
15-18	724	27.74	10.50	1	28	30	30	90
19-21	972	27.63	9.40	1	30	30	30	90
22-44	9,576	27.68	8.32	1	30	30	30	90
45-64	4,063	28.00	8.68	1	30	30	30	154
65-74	55	25.73	9.74	1	25	30	30	60
75+	13	33.08	13.16	10	30	30	30	60
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	16,516	27.78	8.63	1	30	30	30	154
00-01	0	-	-	-	-	-	-	-
02-04	11	27.18	6.59	10	30	30	30	30
05-09	437	27.71	8.72	1	30	30	30	90
10-14	845	27.76	8.95	1	30	30	30	90
15-18	720	27.77	10.50	1	28	30	30	90
19-21	965	27.64	9.40	1	30	30	30	90
22-44	9,467	27.70	8.33	1	30	30	30	90
45-64	4,004	28.03	8.67	1	30	30	30	154
65-74	54	25.65	9.81	1	25	30	30	60
75+	13	33.08	13.16	10	30	30	30	60
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	16,446	27.79	8.64	1	30	30	30	154
00-01	0	-	-	-	-	-	-	-
02-04	11	27.18	6.59	10	30	30	30	30
05-09	437	27.71	8.72	1	30	30	30	90
10-14	844	27.76	8.96	1	30	30	30	90
15-18	720	27.77	10.50	1	28	30	30	90
19-21	961	27.65	9.40	1	30	30	30	90
22-44	9,419	27.71	8.33	1	30	30	30	90
45-64	3,987	28.03	8.68	1	30	30	30	154
65-74	54	25.65	9.81	1	25	30	30	60
75+	13	33.08	13.16	10	30	30	30	60
Sandoz Mixed Amphetamine Salt, 0 Day Gap	329,472	30.96	11.65	1	30	30	30	750
00-01	0	-	-	-	-	-	-	-
02-04	444	31.47	12.57	1	30	30	30	100
05-09	11,055	30.87	11.27	1	30	30	30	220
10-14	16,267	31.62	12.50	1	30	30	30	180
15-18	17,277	31.85	13.14	1	30	30	30	180
19-21	26,257	31.35	12.41	1	30	30	30	200
22-44	187,855	30.66	11.28	1	30	30	30	750
45-64	68,521	31.24	11.72	1	30	30	30	200
65-74	1,717	32.02	13.76	1	30	30	30	100

Table 5c: Descriptive statistics of days supplied per dispensing, by age group (years)								
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
75+	79	33.18	14.49	5	30	30	30	100
Sandoz Mixed Amphetamine Salt, 7 Day Gap	315,220	30.94	11.66	1	30	30	30	750
00-01	0	-	-	-	-	-	-	-
02-04	435	30.68	10.64	1	30	30	30	100
05-09	10,759	30.85	11.20	1	30	30	30	220
10-14	15,758	31.64	12.54	1	30	30	30	180
15-18	16,863	31.86	13.17	1	30	30	30	180
19-21	25,374	31.32	12.42	1	30	30	30	200
22-44	179,428	30.63	11.28	1	30	30	30	750
45-64	64,985	31.23	11.75	1	30	30	30	200
65-74	1,558	31.67	13.31	1	30	30	30	100
75+	60	34.18	16.53	5	30	30	30	100
Sandoz Mixed Amphetamine Salt, 14 Day Gap	307,531	30.91	11.62	1	30	30	30	750
00-01	0	-	-	-	-	-	-	-
02-04	431	30.68	10.69	1	30	30	30	100
05-09	10,584	30.84	11.21	1	30	30	30	220
10-14	15,413	31.58	12.43	1	30	30	30	180
15-18	16,668	31.88	13.22	1	30	30	30	180
19-21	24,820	31.33	12.47	1	30	30	30	200
22-44	174,874	30.60	11.24	1	30	30	30	750
45-64	63,134	31.19	11.67	1	30	30	30	200
65-74	1,555	31.58	13.06	1	30	30	30	100
75+	52	34.83	17.69	5	30	30	30	100
SpecGx Mixed Amphetamine Salt, 0 Day Gap	84,131	29.98	8.88	1	30	30	30	195
00-01	0	-	-	-	-	-	-	-
02-04	14	30.00	0.00	30	30	30	30	30
05-09	1,289	29.75	6.77	1	30	30	30	90
10-14	3,090	30.21	8.55	1	30	30	30	90
15-18	3,737	30.18	9.05	1	30	30	30	151
19-21	5,307	30.27	9.46	1	30	30	30	150
22-44	49,957	29.77	8.42	1	30	30	30	195
45-64	20,185	30.31	9.67	1	30	30	30	102
65-74	518	31.95	15.25	1	30	30	30	180
75+	34	37.68	22.37	12	30	30	30	90

Table 6a: Descriptive statistics of the length of all gaps between treatment episodes, in days ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	726	40.57	66.05	1	6	20	46	761
Barr Mixed Amphetamine Salt, 7 Day Gap	495	48.96	72.87	1	11	24	57	754
Barr Mixed Amphetamine Salt, 14 Day Gap	397	51.76	77.19	1	11	23	61	747
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	4,768	16.70	19.65	1	3	8	26	135
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	2,439	22.44	20.32	1	6	18	30	128
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	1,754	22.75	19.54	1	9	17	31	121
Sandoz Mixed Amphetamine Salt, 0 Day Gap	146,033	69.08	173.65	1	5	19	58	2,228
Sandoz Mixed Amphetamine Salt, 7 Day Gap	96,539	93.93	204.57	1	12	30	84	2,221
Sandoz Mixed Amphetamine Salt, 14 Day Gap	77,845	107.18	221.60	1	14	37	100	2,214
SpecGx Mixed Amphetamine Salt, 0 Day Gap	30,323	72.85	168.41	1	5	20	63	1,794

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	726	40.57	66.05	1	6	20	46	761
Female	380	36.51	57.11	1	6	21	41	690
Male	346	45.02	74.48	1	7	18	50	761
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	495	48.96	72.87	1	11	24	57	754
Female	259	43.53	63.26	1	12	23	52	683
Male	236	54.93	81.85	1	10	26	71	754
Other	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	397	51.76	77.19	1	11	23	61	747
Female	207	44.08	66.28	1	10	21	50	676
Male	190	60.13	86.95	1	11	29	74	747
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	4,768	16.70	19.65	1	3	8	26	135
Female	2,475	16.90	20.23	1	3	8	26	135
Male	2,293	16.47	19.01	1	3	8	26	126
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	2,439	22.44	20.32	1	6	18	30	128
Female	1,261	22.96	21.11	1	7	19	31	128
Male	1,178	21.89	19.45	1	6	18	30	119
Other	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	1,754	22.75	19.54	1	9	17	31	121
Female	914	23.29	20.43	1	9	17	32	121
Male	840	22.17	18.52	1	10	17	29	112
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 0 Day Gap	146,033	69.08	173.65	1	5	19	58	2,228
Female	77,628	69.52	174.18	1	5	19	58	2,182
Male	68,405	68.57	173.03	1	5	19	59	2,228
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 7 Day Gap	96,539	93.93	204.57	1	12	30	84	2,221
Female	51,554	94.08	204.73	1	12	29	83	2,175
Male	44,985	93.74	204.39	1	12	30	85	2,221
Other	0	-	-	-	-	-	-	-
Sandoz Mixed Amphetamine Salt, 14 Day Gap	77,845	107.18	221.60	1	14	37	100	2,214
Female	41,456	107.54	221.74	1	14	36	100	2,168
Male	36,389	106.76	221.45	1	14	38	100	2,214
Other	0	-	-	-	-	-	-	-
SpecGx Mixed Amphetamine Salt, 0 Day Gap	30,323	72.85	168.41	1	5	20	63	1,794
Female	15,621	75.11	175.58	1	5	20	65	1,794

Table 6b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Male	14,702	70.44	160.42	1	5	20	61	1,779
Other	0	-	-	-	-	-	-	-

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported

Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years) ¹								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Barr Mixed Amphetamine Salt, 0 Day Gap	726	40.57	66.05	1	6	20	46	761
00-01	0	-	-	-	-	-	-	-
02-04	9	8.33	7.65	1	3	7	12	25
05-09	86	31.77	56.12	1	6	13	30	358
10-14	131	54.76	88.54	1	9	25	74	761
15-18	62	46.32	46.44	3	17	35	64	269
19-21	58	42.95	58.40	1	7	21	59	311
22-44	254	39.59	66.78	1	5	22	43	690
45-64	124	30.54	52.32	1	5	15	30	364
65-74	2	132.50	102.53	60	60	133	205	205
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 7 Day Gap	495	48.96	72.87	1	11	24	57	754
00-01	0	-	-	-	-	-	-	-
02-04	3	10.00	7.00	5	5	7	18	18
05-09	57	38.77	64.70	1	6	17	40	351
10-14	98	60.70	92.58	1	11	29	78	754
15-18	50	46.98	47.83	2	15	32	60	262
19-21	38	54.68	64.04	1	13	37	70	304
22-44	168	49.71	75.32	1	14	25	54	683
45-64	79	38.22	60.86	1	8	18	32	357
65-74	2	125.50	102.53	53	53	126	198	198
75+	0	-	-	-	-	-	-	-
Barr Mixed Amphetamine Salt, 14 Day Gap	397	51.76	77.19	1	11	23	61	747
00-01	0	-	-	-	-	-	-	-
02-04	1	11.00	-	11	11	11	11	11
05-09	37	50.27	74.16	1	10	20	45	344
10-14	83	63.75	97.31	1	11	35	75	747
15-18	47	42.68	48.08	2	15	29	54	255
19-21	32	57.34	65.45	2	11	39	72	297
22-44	137	50.45	78.93	1	11	22	51	676
45-64	58	41.36	66.72	1	8	16	37	350
65-74	2	118.50	102.53	46	46	119	191	191
75+	0	-	-	-	-	-	-	-
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	4,768	16.70	19.65	1	3	8	26	135
00-01	0	-	-	-	-	-	-	-
02-04	3	13.33	12.06	2	2	12	26	26
05-09	144	18.03	24.23	1	3	9	25	135
10-14	274	17.04	17.96	1	3	9	26	81

Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
15-18	199	18.23	21.53	1	3	10	26	131
19-21	297	17.09	19.84	1	3	9	24	106
22-44	2,637	16.48	19.46	1	3	8	26	124
45-64	1,202	16.54	19.50	1	3	8	26	126
65-74	9	17.00	16.07	2	6	12	24	47
75+	3	30.67	26.41	2	2	36	54	54
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	2,439	22.44	20.32	1	6	18	30	128
00-01	0	-	-	-	-	-	-	-
02-04	2	12.00	9.90	5	5	12	19	19
05-09	77	23.65	27.37	1	4	15	31	128
10-14	148	21.55	17.67	1	7	18	32	74
15-18	113	22.77	22.50	1	6	16	33	124
19-21	167	20.89	20.76	1	5	14	30	99
22-44	1,321	22.59	20.08	1	7	19	30	117
45-64	603	22.59	20.00	1	7	19	29	119
65-74	6	16.83	15.59	2	5	12	31	40
75+	2	38.00	12.73	29	29	38	47	47
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	1,754	22.75	19.54	1	9	17	31	121
00-01	0	-	-	-	-	-	-	-
02-04	1	12.00	-	12	12	12	12	12
05-09	49	28.14	28.51	1	9	19	34	121
10-14	110	20.84	16.55	1	8	19	28	73
15-18	78	24.41	22.14	2	9	16	35	117
19-21	105	23.65	20.24	1	8	18	32	92
22-44	963	22.62	19.20	1	10	17	30	110
45-64	443	22.41	19.18	1	10	17	30	112
65-74	3	22.33	11.59	10	10	24	33	33
75+	2	31.00	12.73	22	22	31	40	40
Sandoz Mixed Amphetamine Salt, 0 Day Gap	146,033	69.08	173.65	1	5	19	58	2,228
00-01	0	-	-	-	-	-	-	-
02-04	149	59.93	206.60	1	4	9	40	1,682
05-09	4,678	63.42	153.63	1	5	18	53	1,884
10-14	7,387	71.64	171.41	1	6	22	61	2,084
15-18	7,967	80.67	183.28	1	7	25	73	2,228
19-21	12,241	78.79	190.28	1	6	22	65	2,182
22-44	81,645	66.90	169.18	1	5	19	57	2,114
45-64	31,188	68.52	179.30	1	5	17	55	2,114
65-74	747	58.88	143.79	1	5	15	46	1,473



Table 6c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
75+	31	79.23	177.03	1	5	19	62	955
Sandoz Mixed Amphetamine Salt, 7 Day Gap	96,539	93.93	204.57	1	12	30	84	2,221
00-01	0	-	-	-	-	-	-	-
02-04	80	99.98	273.80	1	8	32	65	1,675
05-09	3,152	83.76	178.89	1	9	26	77	1,877
10-14	5,260	90.61	194.96	1	12	30	82	2,077
15-18	5,779	101.85	207.48	1	13	35	98	2,221
19-21	8,546	103.05	219.65	1	12	32	97	2,175
22-44	53,349	91.65	200.10	1	12	29	83	2,107
45-64	19,897	96.52	215.02	1	11	29	83	2,107
65-74	460	81.37	172.75	1	9	25	72	1,466
75+	16	131.63	232.10	3	19	48	155	948
Sandoz Mixed Amphetamine Salt, 14 Day Gap	77,845	107.18	221.60	1	14	37	100	2,214
00-01	0	-	-	-	-	-	-	-
02-04	59	124.51	312.72	1	20	40	79	1,668
05-09	2,463	98.27	195.90	1	12	32	94	1,870
10-14	4,243	102.32	210.48	1	13	34	96	2,070
15-18	4,815	113.67	221.24	1	15	42	111	2,214
19-21	6,960	117.36	237.30	1	14	39	111	2,168
22-44	43,119	104.19	216.78	1	14	37	97	2,055
45-64	15,823	111.62	233.88	1	14	37	101	2,100
65-74	349	99.23	192.18	1	13	32	94	1,459
75+	14	142.79	243.55	5	18	48	180	941
SpecGx Mixed Amphetamine Salt, 0 Day Gap	30,323	72.85	168.41	1	5	20	63	1,794
00-01	0	-	-	-	-	-	-	-
02-04	6	34.17	26.66	16	18	25	34	87
05-09	471	51.83	116.99	1	4	14	52	1,766
10-14	1,224	63.26	131.04	1	6	21	60	1,383
15-18	1,458	68.53	150.93	1	7	23	62	1,747
19-21	1,960	89.12	198.38	1	6	24	75	1,581
22-44	17,316	71.47	165.83	1	5	20	62	1,794
45-64	7,678	75.93	177.46	1	5	20	65	1,792
65-74	197	58.25	130.04	1	5	17	59	1,327
75+	13	23.23	26.57	4	5	14	21	80

¹For drugs with pre-specified allowable episode gap and extension, gaps observed between treatment episodes are estimated after dispensings within allowable episode gap are bridged and episode extension applied at the end of the last dispensing. If no episode gap or extension is specified, observed gaps between dispensings for drug of interest are reported.



Table 7: Counts of reason for censoring, all episodes and first episode

	Total		Disenrollment		Evidence of death		DP/Query end date		Episode end	
	N	%	N	%	N	%	N	%	N	%
Episodes										
Barr Mixed Amphetamine Salt, 0 Day Gap	1,566	100.0	69	4.4	0	0.0	0	0.0	1,566	100.0
Barr Mixed Amphetamine Salt, 7 Day Gap	1,323	100.0	73	5.5	0	0.0	0	0.0	1,252	94.6
Barr Mixed Amphetamine Salt, 14 Day Gap	1,219	100.0	81	6.6	0	0.0	0	0.0	1,140	93.5
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	13,060	100.0	3,445	26.4	0	0.0	3,024	23.2	13,060	100.0
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	10,629	100.0	4,014	37.8	0	0.0	3,554	33.4	6,653	62.6
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	9,903	100.0	4,500	45.4	0	0.0	4,015	40.5	5,446	55.0
Sandoz Mixed Amphetamine Salt, 0 Day Gap	245,450	100.0	17,961	7.3	3	0.0	7,474	3.0	245,447	100.0
Sandoz Mixed Amphetamine Salt, 7 Day Gap	194,170	100.0	20,053	10.3	3	0.0	8,637	4.4	174,372	89.8
Sandoz Mixed Amphetamine Salt, 14 Day Gap	174,361	100.0	22,053	12.6	3	0.0	9,719	5.6	152,590	87.5
SpecGx Mixed Amphetamine Salt, 0 Day Gap	68,049	100.0	5,212	7.7	0	0.0	2,709	4.0	68,049	100.0
Patients' First Episode										
Barr Mixed Amphetamine Salt, 0 Day Gap	840	100.0	28	3.3	0	0.0	0	0.0	840	100.0
Barr Mixed Amphetamine Salt, 7 Day Gap	828	100.0	35	4.2	0	0.0	0	0.0	795	96.0
Barr Mixed Amphetamine Salt, 14 Day Gap	822	100.0	44	5.4	0	0.0	0	0.0	780	94.9
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	8,292	100.0	1,768	21.3	0	0.0	1,471	17.7	8,292	100.0
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	8,190	100.0	2,758	33.7	0	0.0	2,343	28.6	5,460	66.7
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	8,149	100.0	3,373	41.4	0	0.0	2,918	35.8	4,811	59.0
Sandoz Mixed Amphetamine Salt, 0 Day Gap	99,417	100.0	6,564	6.6	2	0.0	2,435	2.4	99,415	100.0
Sandoz Mixed Amphetamine Salt, 7 Day Gap	97,631	100.0	8,991	9.2	2	0.0	3,280	3.4	88,767	90.9
Sandoz Mixed Amphetamine Salt, 14 Day Gap	96,516	100.0	10,892	11.3	2	0.0	4,005	4.1	85,767	88.9
SpecGx Mixed Amphetamine Salt, 0 Day Gap	37,726	100.0	2,681	7.1	0	0.0	1,351	3.6	37,726	100.0

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Barr Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,571 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,571 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,560 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,560 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,355 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	1,355 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	840 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	840 (0.0%)
Barr Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,571 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,571 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,553 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,553 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,340 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	1,340 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	828 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	828 (0.0%)
Barr Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,571 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,571 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,546 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,546 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,330 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	1,330 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	822 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	822 (0.0%)
NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	15,336 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	13,512 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	13,512 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	8,292 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	8,292 (0.0%)
NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	15,336 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	15,336 (0.0%)

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	13,460 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	13,460 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	8,190 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	8,190 (0.0%)
NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	15,336 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	15,336 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	13,431 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	13,431 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	8,149 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	8,149 (0.0%)
Sandoz Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	181,820 (0.2%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	181,820 (0.2%)
Exclusion - Members must have at least one episode defining index claim during the query period	180,607 (0.2%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	180,607 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	153,742 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	153,742 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	99,417 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	99,417 (0.1%)
Sandoz Mixed Amphetamine Salt, 7 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	181,820 (0.2%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	181,820 (0.2%)
Exclusion - Members must have at least one episode defining index claim during the query period	179,886 (0.2%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	179,886 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	151,970 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	151,970 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	97,631 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	97,631 (0.1%)
Sandoz Mixed Amphetamine Salt, 14 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	181,820 (0.2%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	181,820 (0.2%)
Exclusion - Members must have at least one episode defining index claim during the query period	179,343 (0.2%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	179,343 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	150,809 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	150,809 (0.2%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	96,516 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	96,516 (0.1%)
SpecGx Mixed Amphetamine Salt, 0 Day Gap	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	92,812,768 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	76,841,715 (82.8%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y during the query period	76,841,715 (82.8%)
Exclusion - Members must satisfy the age range condition within the query period	76,840,263 (82.8%)
Exclusion - Members must meet chart availability criterion within the query period	76,840,263 (82.8%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	76,840,263 (82.8%)

Table 8: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	69,571 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	69,571 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	58,661 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	58,661 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	37,726 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	37,726 (0.0%)

Appendix A. Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2019) as of Query Distribution Date

Data Partner	Start Date	End Date
DP01	01/01/2010	03/31/2019

Appendix B. Specifications Used to Define Parameters in this Query

Global Values

Enrollment Criteria: **Medical and Drug Coverage**

Enrollment Gap (Days) **45**

Age Groups (Years): **00-01, 02-04, 05-09, 10-14, 15-18, 19-21, 22-44, 45-64, 65-74, 75+**

Query Period: **01/01/2013-03/31/2019**

Baseline Characteristics Table: **Yes**

Baseline Evaluation Window (Day): **-183,0**

#	Cohort Name	Index Exposure	Pre-Index Enrollment Period (Days)	Washout Period (Days)	Treatment Episode Gap (Days)	Treatment Episode Extension (Days)	Inclusion/Exclusion	Criteria	Criteria Definition	Evaluation Period Start (Day)	Evaluation Period End (Day)
1	Sandoz Mixed Amphetamine Salt, 0 Day Gap	Sandoz MAS IR ^[1]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[2]	-183	0
2	Sandoz Mixed Amphetamine Salt, 7 Day Gap	Sandoz MAS IR ^[3]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[4]	-183	0
3	Sandoz Mixed Amphetamine Salt, 14 Day Gap	Sandoz MAS IR ^[5]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[6]	-183	0
4	NorthstarRx Mixed Amphetamine Salt, 0 Day Gap	MAS IR_NorthstarRx ^[7]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[8]	-183	0
5	NorthstarRx Mixed Amphetamine Salt, 7 Day Gap	MAS IR_NorthstarRx ^[9]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[10]	-183	0
6	NorthstarRx Mixed Amphetamine Salt, 14 Day Gap	MAS IR_NorthstarRx ^[11]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[12]	-183	0
7	Barr Mixed Amphetamine Salt, 0 Day Gap	MAS IR_Barr ^[13]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[14]	-183	0
8	Barr Mixed Amphetamine Salt, 7 Day Gap	MAS IR_Barr ^[15]	183	0	7	7	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[16]	-183	0
9	Barr Mixed Amphetamine Salt, 14 Day Gap	MAS IR_Barr ^[17]	183	0	14	14	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[18]	-183	0
10	SpecGx Mixed Amphetamine Salt, 0 Day Gap	MAS IR_SpecGx ^[19]	183	0	0	0	Inclusion	Narcolepsy/ADHD	Narcolepsy/ADHD ^[20]	-183	0

ICD-9, ICD-10, HCPCS AND CPT are provided by Optum360
NDCs are checked against First Data Bank's MedKnowledge.

Appendix of Generic Names and Chronic Conditions

- [1] See Appendix C
- [2] See Appendix D
- [3] See Appendix C
- [4] See Appendix D
- [5] See Appendix C
- [6] See Appendix D
- [7] See Appendix C
- [8] See Appendix D
- [9] See Appendix C
- [10] See Appendix D
- [11] See Appendix C
- [12] See Appendix D
- [13] See Appendix C
- [14] See Appendix D
- [15] See Appendix C
- [16] See Appendix D
- [17] See Appendix C
- [18] See Appendix D
- [19] See Appendix C
- [20] See Appendix D

Baseline Characteristics Table

Acquired Hypothyroidism	Chronic Kidney Disease	Hypertension
Acute Myocardial Infarction	Chronic Obstructive Pulmonary Disease	Ischemic Heart Disease
Alzheimer's Disease	Colorectal Cancer	Lung Cancer
Alzheimer's Disease, Related Disorders, or Senile Dementia	Depression	Osteoporosis
Anemia	Diabetes	Prostate Cancer
Asthma	Endometrial Cancer	Rheumatoid Arthritis / Osteoarthritis
Atrial Fibrillation	Glaucoma	Stroke / Transient Ischemic Attack
Benign Prostatic Hyperplasia	Heart Failure	
Breast Cancer	Hip / Pelvic Fracture	
Cataracts	Hyperlipidemia	

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module

- Age Groups** - Age groups of members included in the cohort. Strata also used for reporting purposes.
- Ambulatory Visit (AV)** - A care setting value including visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Baseline Characteristics Table** - Optional table containing general characteristics of study population, including background rates of 27 chronic conditions from the CMS Chronic Condition Warehouse (see above if table requested). Users define an evaluation period for the presence of baseline characteristics.
- Care Setting** - Type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.
- Charlson/Elixhauser Combined Comorbidity Score** - Calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
- Cohort Definition** - Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using the washout period.
- Emergency Department (ED)** - A care setting value including ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Enrollment Criteria** - Type of coverage required during enrollment period. By default, all patients must have medical and drug coverage.
- Enrollment Gap** - Allowed gap between coverage periods.
- Episodes** - Treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
- Inclusion/Exclusion** - Contains the comprehensive set of codes used to define additional cohort inclusion and/or exclusion criteria (e.g., restrict cohort to individuals with evidence of a pre-existing condition 183 days before the index date). Criteria could be defined with complex algorithms (e.g., diagnosis codes and drug codes) defined under Criteria Definition.
- Inpatient Hospital Stay (IP)** - A care setting value including all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS)** - A care setting value including hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA)** - A care setting value including other non-overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.
- Principal Diagnosis (PDX)** - Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.
- Query Period** - The period of time which patients can contribute index-defining exposure/events. Data prior to the start date may be used to determine enrollment, washout, and other cohort inclusion criteria.
- Treatment Episode Extension** - The episode extension adds the selected number of days to the end of an episode to count as exposed time.
- Treatment Episode Gap** - The maximum number of days allowed between two dispensings to consider them part of the same episode.
- Washout Period** - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Appendix C. List of National Drug Codes (NDCs) and Generic Names of Medical Products Used to Define Index Exposure in this Request

NDC	Generic Name
Sandoz Mixed Amphetamine Salt Immediate Release	
00185008401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185011101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185040101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185040401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185083101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185084201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185085301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00185086401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
NorthstarRx Mixed Amphetamine Salt Immediate Release	
16714080201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080501	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080601	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080701	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714080801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714094801	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714094901	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714095001	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714095101	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714095201	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714095301	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
16714095401	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
Barr Mixed Amphetamine Salt Immediate Release	
00555076202	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00555076302	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
00555076602	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
SpecGx Mixed Amphetamine Salt Immediate Release	
004068884	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
004068885	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
004068891	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
004068892	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
004068893	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate
004068894	dextroamphetamine sulf-saccharate/amphetamine sulf-aspartate

Appendix D. List of International Classifications of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classifications of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
Attention-Deficit/Hyperactivity Disorder (ADHD)			
312.00	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, unspecified
312.01	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, mild
312.02	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, moderate
312.03	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, aggressive type, severe
312.10	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, unspecified
312.11	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, mild
312.12	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, moderate
312.13	Diagnosis	ICD-9-CM	Undersocialized conduct disorder, unaggressive type, severe
312.20	Diagnosis	ICD-9-CM	Socialized conduct disorder, unspecified
312.21	Diagnosis	ICD-9-CM	Socialized conduct disorder, mild
312.22	Diagnosis	ICD-9-CM	Socialized conduct disorder, moderate
312.23	Diagnosis	ICD-9-CM	Socialized conduct disorder, severe
312.30	Diagnosis	ICD-9-CM	Impulse control disorder, unspecified
312.31	Diagnosis	ICD-9-CM	Pathological gambling
312.32	Diagnosis	ICD-9-CM	Kleptomania
312.33	Diagnosis	ICD-9-CM	Pyromania
312.34	Diagnosis	ICD-9-CM	Intermittent explosive disorder
312.35	Diagnosis	ICD-9-CM	Isolated explosive disorder
312.39	Diagnosis	ICD-9-CM	Other disorder of impulse control
312.4	Diagnosis	ICD-9-CM	Mixed disturbance of conduct and emotions
312.81	Diagnosis	ICD-9-CM	Conduct disorder, childhood onset type
312.82	Diagnosis	ICD-9-CM	Conduct disorder, adolescent onset type
312.89	Diagnosis	ICD-9-CM	Other specified disturbance of conduct, not elsewhere classified
312.9	Diagnosis	ICD-9-CM	Unspecified disturbance of conduct
314.00	Diagnosis	ICD-9-CM	Attention deficit disorder of childhood without mention of hyperactivity
314.01	Diagnosis	ICD-9-CM	Attention deficit disorder of childhood with hyperactivity
314.1	Diagnosis	ICD-9-CM	Hyperkinesis of childhood with developmental delay
314.2	Diagnosis	ICD-9-CM	Hyperkinetic conduct disorder of childhood
314.8	Diagnosis	ICD-9-CM	Other specified manifestations of hyperkinetic syndrome of childhood
314.9	Diagnosis	ICD-9-CM	Unspecified hyperkinetic syndrome of childhood
F63.0	Diagnosis	ICD-10-CM	Pathological gambling
F63.1	Diagnosis	ICD-10-CM	Pyromania
F63.2	Diagnosis	ICD-10-CM	Kleptomania
F63.3	Diagnosis	ICD-10-CM	Trichotillomania
F63.81	Diagnosis	ICD-10-CM	Intermittent explosive disorder
F63.89	Diagnosis	ICD-10-CM	Other impulse disorders
F63.9	Diagnosis	ICD-10-CM	Impulse disorder, unspecified
F90.0	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, predominantly inattentive type
F90.1	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, predominantly hyperactive type
F90.2	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, combined type

Appendix D. List of International Classifications of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classifications of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
F90.8	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, other type
F90.9	Diagnosis	ICD-10-CM	Attention-deficit hyperactivity disorder, unspecified type
F91.0	Diagnosis	ICD-10-CM	Conduct disorder confined to family context
F91.1	Diagnosis	ICD-10-CM	Conduct disorder, childhood-onset type
F91.2	Diagnosis	ICD-10-CM	Conduct disorder, adolescent-onset type
F91.3	Diagnosis	ICD-10-CM	Oppositional defiant disorder
F91.8	Diagnosis	ICD-10-CM	Other conduct disorders
F91.9	Diagnosis	ICD-10-CM	Conduct disorder, unspecified
Narcolepsy			
347	Diagnosis	ICD-9-CM	Cataplexy and narcolepsy
347.0	Diagnosis	ICD-9-CM	Narcolepsy
347.00	Diagnosis	ICD-9-CM	Narcolepsy, without cataplexy
347.01	Diagnosis	ICD-9-CM	Narcolepsy, with cataplexy
347.1	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere
347.10	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere, without cataplexy
347.11	Diagnosis	ICD-9-CM	Narcolepsy in conditions classified elsewhere, with cataplexy
G47.4	Diagnosis	ICD-10-CM	Narcolepsy and cataplexy
G47.41	Diagnosis	ICD-10-CM	Narcolepsy
G47.411	Diagnosis	ICD-10-CM	Narcolepsy with cataplexy
G47.419	Diagnosis	ICD-10-CM	Narcolepsy without cataplexy
G47.42	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere
G47.421	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere with cataplexy
G47.429	Diagnosis	ICD-10-CM	Narcolepsy in conditions classified elsewhere without cataplexy